Slapke J, Hummel S, Jäger L
Z Gesamte Inn Med. 1979 Dec 1;34(23):698-701.
Central pathogenetic mechanism of the analgesics-asthma-syndrome is very probably an analgesics-conditioned inhibition of the prostaglandin-biosynthesis (cyclooxygenase). Salicylamide, an analgesic without effect on the prostaglandin synthesis was in the oral exposition test of 18 patients with proved analgesics-asthma-syndrome in the dosage of 500 mg subjectively and objectively tolerated without reaction. Body-plethysmographically in consistent thoracic gas volume a slight decrease of the airways resistance could be registered. At the model of the isolated trachea of guinea-pigs salicylamide, in contrast to indomethacin and phenazone (prostaglandin-synthesis inhibitory substances) did not lead to an increase of the acetylcholine-induced spasm. Salcylamide can, after a tolerability test, be recommended as alternative analgesic in the analgesics-asthma-syndrome in a dosage of 500 mg.
镇痛药 - 哮喘综合征的核心发病机制很可能是镇痛药对前列腺素生物合成（环氧化酶）的条件性抑制。水杨酰胺是一种对前列腺素合成无影响的镇痛药，在对18例已证实患有镇痛药 - 哮喘综合征的患者进行的口服暴露试验中，500毫克剂量的水杨酰胺在主观和客观上都能耐受且无反应。人体体积描记法显示，在胸腔气体体积一致的情况下，气道阻力略有下降。在豚鼠离体气管模型中，与吲哚美辛和非那宗（前列腺素合成抑制物质）不同，水杨酰胺不会导致乙酰胆碱诱导的痉挛增加。经过耐受性测试后，水杨酰胺可以推荐作为镇痛药 - 哮喘综合征的替代镇痛药，剂量为500毫克。
